Print this page
-
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Protocol: 072311Principal Investigator:
- Sharon Li (Rutgers University)
Applicable Disease Sites: Liver -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
- Sharon Li (Rutgers University)
Applicable Disease Sites: Liver -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Liver -
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT).
Protocol: 111806Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Liver -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Liver
Any Site
Other Digestive Organ -
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Protocol: 001720Principal Investigator:
- Vinod Rustgi MD, MBA (Archived - Rutgers Robert Wood Johnson Medical School)
Applicable Disease Sites: Liver